Imunon (IMNN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing non-viral DNA technology for immunotherapies and vaccines targeting cancer and infectious diseases.

• Lead program IMNN-001 is a DNA-based immunotherapy for advanced ovarian cancer in Phase II; also developing a COVID-19 booster vaccine (IMNN-101).

• Focus on harnessing the body's natural mechanisms for durable, safe, and effective responses.

Financial performance and metrics

• Positive topline data from Phase 2 OVATION 2 trial: median time to event (experimental vs control) 40.5 vs 29.4 months; hazard ratio 0.74.

• 14,400,889 shares of common stock outstanding as of August 26, 2024.

• Last reported sale price of common stock was $1.07 per share on September 19, 2024.

Use of proceeds and capital allocation

• Will not receive proceeds from resale by selling stockholders; will receive up to $10 million if all warrants are exercised for cash.

• Any proceeds from warrant exercises will be used for general corporate purposes, including working capital.